In short
This article discusses a clinical trial investigating the use of Rilpivirine Hydrochloride as part of an antiretroviral treatment regimen for HIV-infected patients with metabolic liver disease. The study aims to assess the drug's effectiveness in slowing the progression or reducing liver fibrosis while maintaining undetectable HIV viral loads. This Phase IV trial compares the efficacy and safety of Rilpivirine-based treatment to other antiretroviral therapies in patients with stable HIV control.
At a glance
- Study Type
- Phase IV comparative, randomized, open-label pilot study
- Main Objective
- Evaluate efficacy of Rilpivirine-based antiretroviral treatment in HIV patients with metabolic liver disease
- Primary Endpoint
- No progression and/or regression of liver fibrosis at month 18
- Key Inclusion Criteria
- HIV-infected adults, stable ART for 6+ months, undetectable viral load, diagnosed metabolic liver disease with fibrosis
- Key Exclusion Criteria
- Chronic HBV/HCV infection, uncontrolled diabetes, alcohol abuse, pregnancy, prior Rilpivirine use
- Study Medication
- Juluca (Dolutegravir 50mg / Rilpivirine 25mg) film-coated tablets
- Treatment Duration
- 18 months
- Dosage
- 1 tablet daily, maximum 540 tablets over study period
What is Rilpivirine Hydrochloride?
Rilpivirine Hydrochloride is an antiretroviral medication used in the treatment of HIV (Human Immunodeficiency Virus) infection. It is often used in combination with other antiretroviral drugs to effectively manage HIV and prevent its progression to AIDS (Acquired Immunodeficiency Syndrome).
Medical Conditions Treated
The primary focus of the clinical trial involving Rilpivirine Hydrochloride is on patients with two specific conditions:
- HIV infection: A viral infection that attacks the body's immune system.
- Metabolic liver disease: A condition affecting the liver's ability to process and store nutrients, often associated with HIV infection.
Overview of the Clinical Study
The clinical trial is a Phase IV study, which means it is conducted after the drug has been approved for use. It aims to evaluate the effectiveness and safety of a Rilpivirine-based antiretroviral treatment regimen in HIV-infected patients who also have metabolic liver disease.
Key features of the study include:
- It is a comparative study, meaning it compares different treatment options.
- It is randomized, which means participants are randomly assigned to different treatment groups.
- It is open-label, meaning both the researchers and participants know which treatment is being given.
- It focuses on patients who maintain an undetectable HIV viral load, which means the amount of HIV in their blood is too low to be detected by standard tests.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key inclusion criteria are:
- Age 18 or older with HIV infection
- No prior treatment with Rilpivirine
- Stable antiretroviral therapy for at least 6 months
- Undetectable HIV viral load for at least 6 months
- Diagnosed with metabolic liver disease and some degree of liver fibrosis (scarring of the liver)
Some exclusion criteria include:
- Chronic hepatitis B or C infection
- History of alcohol abuse
- Pregnancy or breastfeeding
- Previous use of Rilpivirine
Study Objectives and Endpoints
The main objective of this study is to evaluate how effective Rilpivirine is, as part of an antiretroviral treatment regimen, in slowing down or reducing liver fibrosis in HIV-infected people with metabolic liver disease.
The primary endpoints (main outcomes) the researchers are looking at include:
- No progression of liver fibrosis after 18 months of treatment
- Reduction in liver fibrosis after 18 months of treatment
These outcomes will be measured using non-invasive tests, which means they don't require a liver biopsy.
Drug Information
In this study, Rilpivirine Hydrochloride is used as part of a combination drug called Juluca. Juluca contains:
- Dolutegravir Sodium: Another antiretroviral medication
- Rilpivirine Hydrochloride: The focus of this study
Juluca comes in the form of film-coated tablets, each containing 50 mg of Dolutegravir and 25 mg of Rilpivirine. The maximum daily dose in the study is one tablet, and the treatment period is up to 18 months.
Potential Benefits
While the study is still ongoing and results are not yet available, the potential benefits of this Rilpivirine-based treatment regimen could include:
- Improved management of HIV infection
- Slowing down or reducing liver fibrosis in patients with metabolic liver disease
- Better understanding of how Rilpivirine affects liver health in HIV patients
It's important to note that these potential benefits are based on the study's objectives and are not guaranteed outcomes. The results of the clinical trial will provide more definitive information about the effectiveness of this treatment approach.